B. Mothe

D. Podzamczer, J. Martinez-Picado, E. Ruiz-Mateos, 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Todd M. Allen, R. Paredes, B. Clotet, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differential prevalence of the HLA-C -- 35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals.

B. Clotet, C. Brander, E. Ballana, 2012, Immunobiology.

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

M. Esteller, B. Clotet, J. Martinez-Picado, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Absence of drug-drug interactions between γ-hydroxybutyric acid (GHB) and cobicistat.

M. Farré, C. Pérez-Mañá, J. Moltó, 2021, The Journal of antimicrobial chemotherapy.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

J. Nabukenya, T. Ndung’u, S. Lewin, 2021, Nature Medicine.

OP 8.3 – 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccine trial

A. Llano, B. Mothe, C. Brander, 2022, Journal of virus eradication.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

J. Martinez-Picado, C. Brander, Felipe García, 2018, AIDS.

Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)

C. Brander, Felipe García, M. Plana, 2016, AIDS.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

B. Clotet, J. Martinez-Picado, C. Brander, 2015, The Journal of antimicrobial chemotherapy.

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

C. Brander, Felipe García, J. Gatell, 2015, PloS one.

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study

C. Brander, Felipe García, J. Nourikyan, 2020, Frontiers in Immunology.

TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses

B. Clotet, À. Olvera, J. Martinez-Picado, 2020, The Journal of Immunology.

Small steps forward for HIV vaccine development

C. Brander, B. Mothe, 2020, Nature Medicine.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution

R. Paredes, B. Clotet, J. Prado, 2022, The Journal of infectious diseases.

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

B. Clotet, J. Segalés, J. Prado, 2022, iScience.

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

B. Clotet, L. Ruiz, C. Brander, 2013, Journal of Translational Medicine.

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

J. Mullins, N. Sardesai, B. Clotet, 2015, Journal of Translational Medicine.

P16-24. Crucial contribution of sub-dominant HLA-C allele restricted CTL responses to the control of HIV

C. Brander, A. Llano, B. Mothe, 2009, Retrovirology.

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

B. Clotet, J. Martinez-Picado, C. Brander, 2014, PloS one.

Altered T‐cell subset distribution in the viral reservoir in HIV‐1‐infected individuals with extremely low proviral DNA (LoViReTs)

B. Clotet, J. Martinez-Picado, V. Urrea, 2022, Journal of internal medicine.

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

M. Esteller, R. Paredes, B. Clotet, 2022, EBioMedicine.

Treatment simplification to once daily darunavir/ ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients

B. Clotet, E. Negredo, S. Videla, 2010, Antiviral therapy.

Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors

J. Gatell, N. Saubí, P. Cardona, 2010, Journal of biomedicine & biotechnology.

Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment

B. Clotet, C. Brander, Xavier Borràs, 2012, Brain, Behavior, and Immunity.

Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination

C. Brander, Felipe García, M. Plana, 2016, AIDS.

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

B. Clotet, T. Wyss-Coray, J. Martinez-Picado, 2023, Journal of virology.

Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients

P. Aloy, Felipe García, M. Plana, 2019, Open forum infectious diseases.

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination

B. Clotet, J. Martinez-Picado, T. Hanke, 2023, EBioMedicine.

Differential Immunodominance Hierarchy of CD8 (cid:2) T-Cell Responses in HLA-B * 27:05- and -B * 27:02-Mediated Control of HIV-1 Infection

B. Walker, M. John, S. Mallal, 2018 .

Differential Immunodominance Hierarchy of CD8 (cid:2) T-Cell Responses in HLA-B * 27:05- and -B * 27:02-Mediated Control of HIV-1 Infection

B. Walker, M. John, S. Mallal, 2018 .

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.

Pathogenesis and Treatment of HIV Infection: The Cellular, the Immune System and the Neuroendocrine Systems Perspective

B. Mothé, C. Brander, G. Bocharov, 2013, International reviews of immunology.

HIV-Infected T Cells Presented by the Class I HLA of Direct Interrogation of Viral Peptides

À. Olvera, C. Brander, M. Plana, 2014 .

Influenza, but not HIV‐specific CTL epitopes, elicits delayed‐type hypersensitivity (DTH) reactions in HIV‐infected patients

C. Brander, N. Bhardwaj, R. Gandhi, 2013, European journal of immunology.

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses

B. Mothe, C. Brander, T. Escribà, 2024, Vaccines.

Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes

B. Mothe, N. Wareham, A. Jödicke, 2024, Nature communications.

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

E. Ruiz-Mateos, B. Mothe, A. Pérez-Gómez, 2024, JCI insight.